Amgen Inc. (AMGN)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Robert A. Bradway | Chairman, CEO & President | 6.73M | -- | 1963 |
Mr. Peter H. Griffith | Executive VP & CFO | 3.07M | -- | 1959 |
Mr. Esteban Santos | Executive Vice President of Operations | 3.01M | -- | 1968 |
Dr. David M. Reese M.D. | Executive VP & Chief Technology Officer | 3.4M | -- | 1963 |
Mr. Murdo Gordon | Executive Vice President of Global Commercial Operations | 3.24M | -- | 1967 |
Mr. Matthew C. Busch | Chief Accounting Officer & VP of Finance | -- | -- | 1974 |
Mr. Mike Zahigian | Senior VP & Chief Information Officer | -- | -- | -- |
Dr. James E. Bradner M.D. | Executive VP of Research and Development & Chief Scientific Officer | -- | -- | 1972 |
Justin G. Claeys | Vice President of Investor Relations | -- | -- | -- |
Mr. Jonathan P. Graham | Executive VP, General Counsel & Secretary | 2.44M | -- | 1961 |
Amgen Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 26,700
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Corporate Governance
Recent Events
- Apr 17, 2024DEFA14A: Proxy StatementsSee Full Filing
- Apr 10, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Feb 14, 202410-K: Periodic Financial ReportsSee Full Filing
- Jan 30, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 25, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
Upcoming Events
Jun 07, 2024
Dividend Date
May 16, 2024
Ex-Dividend Date